Retatrutide
LY3437943; "triple G"; "Reta"; "the Godzilla peptide" (community); GGG tri-agonist
The Ground Truth Score
four plain questions, never one numberBest-in-class trial data, still investigational, gray-market reality
Bottom line
Genuinely strong human RCT evidence for the largest weight loss of any GLP-1-class drug yet, but it is NOT FDA-approved, so every gram in circulation is unregulated research-grade material of unknown identity and purity.
Does the science back it?
Do real people feel it?
Is it safe?
Could it be placebo?
"Do real people feel it?" is anecdote, not proof, weighted up because the science is thin, never because it beats a trial. And "could it be placebo?" is not an insult: if you feel better, that's real to you. The point is only to know whether you're paying peptide prices for an expectation.
Why is the evidence this thin? It's mostly economics →
Dose at a glance
full dosing ↓Trials used once-weekly subcutaneous injection with slow titration: typically starting 2 mg/week, escalating monthly toward maintenance doses of 4, 8, or 12 mg.
Reported, not prescribed. Verify your vial and your math.
First documented human use
First-in-human Phase 1 single/multiple-ascending-dose studies in healthy adults and adults with type 2 diabetes began ~2019-2020 (Eli Lilly, LY3437943); first peer-reviewed human data published in The Lancet in 2022 (Phase 1b/2 multiple-ascending-dose, T2D). Pivotal Phase 2 obesity trial published NEJM, online June 26, 2023.
The pitch
What people claim it does
Stated plainly and neutrally, exactly as you'll hear it. I grade each one below.
- Once-weekly triple agonist (GLP-1 + GIP + glucagon) producing the largest mean weight loss reported for any incretin drug in trials, up to ~24% at 48 wks (Phase 2) and ~25-30% at 80 wks (Phase 3 TRIUMPH-1 topline).
- The added glucagon arm raises energy expenditure and drives strong liver-fat reduction, a mechanism distinct from semaglutide/tirzepatide and a likely edge in MASLD.
- Community-reported appetite/food-noise suppression is profound, and trial participants kept losing weight through 68-80 weeks without the typical plateau.
The data behind each bullet
What actually backs it
Phase 2 obesity RCT (n=338, 48 wks): mean weight loss -24.2% at 12 mg vs -2.1% placebo; 83% of 12 mg group lost ≥15% body weight.
Double-blind, randomized, placebo-controlled Phase 2 trial published in NEJM (Jastreboff et al., 2023).
PubMed: Retatrutide Phase 2 obesity trial (NEJM 2023) ↗Phase 3 TRIUMPH-1 (obesity without diabetes, ~2,339 pts, 80 wks): all doses met primary/key secondary endpoints; up to ~25% (treatment-regimen) to ~30% (efficacy estimand) mean weight loss; ~65% on 12 mg reached BMI <30.
Company-reported topline of a pivotal Phase 3 RCT (May 2026); full peer-reviewed publication pending at time of writing.
ClinicalTrials.gov: TRIUMPH-1 (NCT05929066) ↗Phase 3 in type 2 diabetes (TRANSCEND-T2D-1, 40 wks): met primary and all key secondary endpoints; A1C reduction ~1.7-2.0% across doses; ~16.8% mean weight loss at 12 mg.
Company-reported topline of a Phase 3 RCT in T2D (2026); full publication pending.
ClinicalTrials.gov: Retatrutide T2D Phase 3 (NCT05929079) ↗Liver fat: Phase 2a MASLD trial showed large reductions in liver fat content (high proportions reaching normal liver-fat thresholds) at 24-48 weeks.
Randomized Phase 2a sub-study published in Nature Medicine (2024).
PubMed: Retatrutide MASLD Phase 2a trial ↗NOT FDA-approved as of June 2026, entirely investigational; no approved finished product exists. Regulatory submission anticipated ~2027 pending Phase 3 completion.
Verifiable absence of any approved label on DailyMed/FDA; drug is in active Phase 3 (TRIUMPH program). This regulatory fact is itself grade-A certain.
DailyMed search: retatrutide (no approved label) ↗Mechanism
How it's assumed to work
Assumed · theoretical pathway
Synthetic single-peptide triple agonist at the GLP-1, GIP, and glucagon receptors. GLP-1 + GIP drive appetite suppression, satiety, and improved insulin response; the added glucagon-receptor agonism is thought to increase energy expenditure and hepatic fat oxidation, contributing to the larger weight loss and strong liver-fat reduction versus dual agonists. Mechanism is well-characterized from extensive Lilly preclinical and clinical pharmacology (not "assumed"), though it remains investigational rather than approved-label.
Dosing & handling
What users and clinicians report
Trials used once-weekly subcutaneous injection with slow titration: typically starting 2 mg/week, escalating monthly toward maintenance doses of 4, 8, or 12 mg. Community/gray-market users mirror this, commonly starting low (~1-2 mg/wk) and titrating up over weeks to manage GI effects, with 4-12 mg as reported maintenance.
REPORTED, not prescribed. Ground Truth does not endorse self-administration of an unapproved drug. There is no verified finished product, so any "dose" assumes a vial actually contains labeled, pure retatrutide, which cannot be confirmed without third-party testing. Rapid escalation drives GI intolerance; titration in trials is deliberately slow. Self-dosing without medical supervision forgoes the contraindication screening, monitoring, and dose adjustment built into the trials.
Timing & food
Once weekly, same day each week, subcutaneous; can be given without regard to meals (food timing not required). In trials, dose is titrated upward at roughly monthly intervals. Taking it at a consistent weekly time and titrating slowly is the main lever community users cite for minimizing nausea; some report dosing in the evening to sleep through early GI effects (anecdotal).
Half-life
Approximately 6 days, supporting once-weekly dosing; dose-proportional pharmacokinetics across the 0.5-12 mg range with no clinically meaningful accumulation beyond expected steady state.
Reconstitution sensitivity
As a peptide drug, retatrutide is reconstituted from lyophilized powder with bacteriostatic or sterile water and is sensitive to vigorous agitation, heat, and light; reconstituted solution should be refrigerated. The larger risk is not handling but provenance, unverified gray-market lyophilate may be underdosed, mislabeled, or contaminated, making reconstitution math meaningless without identity/purity testing.
Real-world signal
What people actually report
Anecdote, not proof, weighted because the science is thin. Here's the record, graded on volume, consistency, and how credible the sources are.
Volume
High. A large, active community (r/Retatrutide ~30K+ members) plus extensive coverage across telehealth, medspa, and peptide-vendor sites. It is one of the most-discussed investigational metabolic compounds online, frequently dubbed the "Godzilla" of weight-loss drugs.
Consistency
High and consistent on the core experience, large weight loss and strong appetite/"food-noise" suppression are near-universal in reports, as are dose-related GI side effects (nausea/fatigue appear in 70%+ of weekly experience threads). Consistency tracks the trial data closely, which raises credibility that real material is circulating, but does not verify any individual vial.
Source credibility
Mixed-to-discounted. The underlying clinical evidence is genuinely top-tier, but most search-surface content is affiliate/commercial (peptide sellers, telehealth funnels, "research-only" vendors) with a strong incentive to overstate safety and downplay that the drug is unapproved. Discount vendor blogs heavily; weight anecdotes carry weight only because they align with independent RCTs, not on their own.
- Overwhelmingly the most-reported benefit is dramatic appetite and 'food-noise' suppression, many users say the psychological relief from constant food thoughts rivals or exceeds the weight loss itself.
- Users frequently report continued weight loss without the plateau they experienced on semaglutide or tirzepatide, and many describe switching to retatrutide specifically to break a stall.
- GI side effects dominate negative reports, nausea, fatigue, and constipation are common, especially during dose escalation; the consensus 'fix' is slower titration and lower starting doses.
- A recurring sober thread is awareness that the drug is unapproved and sourced gray-market, with experienced users urging third-party purity testing and cautioning newcomers that vial contents and dosing are unverifiable.
Placebo risk, Low
Weight loss is an objective, measurable endpoint (scale, BMI, body composition), and the magnitude seen (20-30%) far exceeds any plausible placebo or expectancy effect, placebo arms lost only ~2-4%. The subjective "food-noise" reduction is more expectancy-prone, but the hard outcome is not, so overall placebo risk is Low.
Risk panel
What could go wrong
Adverse events
Most common are dose-related gastrointestinal events (nausea, vomiting, diarrhea, constipation), nausea ~60% at 12 mg in trials, mostly mild-to-moderate. Dose-dependent resting heart rate increase (~5-7 bpm, peaking ~24 wks then declining). Decreased appetite, fatigue. In Phase 2, serious adverse events were comparable to placebo (~4% both arms).
Theoretical concerns
Glucagon-receptor agonism can transiently raise fasting glucose and is theoretically counterproductive in poorly controlled diabetes (net effect in trials was glucose-lowering, as GLP-1 dominates). Class-effect rodent thyroid C-cell tumors underlie the boxed-warning concern (human relevance debated). Potential for increased heart rate to matter in susceptible cardiac patients pending CV-outcome data.
Contraindications
Contraindicated (class labeling for GLP-1 agonists) in personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2). Caution/avoid with history of pancreatitis, severe GI disease/gastroparesis, active gallbladder disease. Not for pregnancy/breastfeeding. Because no approved product exists, there is no prescriber-vetted contraindication screen for gray-market users.
Honest unknowns
No FDA-approved product means no quality-controlled finished drug, gray-market vials carry unknown identity, purity, dose accuracy, and sterility risk. Long-term (>80 wk) safety, cardiovascular-outcome data, and post-marketing surveillance do not yet exist. Effects of rapid 25-30% weight loss on lean mass, bone, and very-low-BMI individuals self-dosing outside trial supervision are unquantified.
Confound watch
Trial results come with diet/lifestyle counseling and dose titration, community results conflate the drug with concurrent calorie restriction. Affiliate/vendor blogs (peptide sellers, telehealth, "research chemical" sites) dominate search results and inflate enthusiasm while underselling that the drug is unapproved. Forum weight-loss numbers cannot verify actual compound identity or dose. Distinguish the legitimate Lilly trial evidence (real) from the gray-market product (uncharacterized).
History
Discovery → first use → status
- ~2019-2020First-in-human Phase 1 single/multiple-ascending-dose studies begin (Eli Lilly, LY3437943) in healthy adults and adults with T2D.
- 2022First peer-reviewed human data published in The Lancet (Phase 1b/2 multiple-ascending-dose in type 2 diabetes); ~6-day half-life supports once-weekly dosing.
- Jun 26, 2023Pivotal Phase 2 obesity RCT published in NEJM, up to 24.2% mean weight loss at 48 weeks; triggers intense media and community attention.
- 2024Phase 2a MASLD (liver) results published in Nature Medicine showing large liver-fat reductions.
- Dec 2025TRIUMPH-4 (obesity + knee osteoarthritis) topline: ~28.7% mean weight loss at 68 wks plus substantial WOMAC pain relief.
- May 21, 2026TRIUMPH-1 pivotal Phase 3 obesity topline announced: bariatric-level weight loss, all doses met endpoints.
- 2026 (ongoing)TRIUMPH-2 (T2D), TRIUMPH-3 (established CV disease) readouts pending; TRANSCEND-T2D-1 met all endpoints. Still no regulatory approval.
Verification
The COA standard, applied
Confirm any vendor vial via independent third-party mass-spec/HPLC purity and identity testing (e.g., Janoshik) before assuming contents; verify reconstitution math against actual labeled mg. Cross-check claims only against primary trial sources (NEJM, Lancet, Nature Medicine, ClinicalTrials.gov, Lilly investor releases), not vendor blogs. Note that no DailyMed/FDA label exists, so there is no official prescribing information to verify dosing against.
The full verification standard →Sources
Where this comes from
- NEJM Phase 2 obesity trial (PubMed) ↗· Pivotal double-blind RCT, n=338, 48 wks; up to -24.2% weight at 12 mg. Primary grade-B evidence.
- Retatrutide T2D phase 2 trial (PubMed) ↗· Phase 2 RCT in type 2 diabetes (Lancet) establishing glycemic + weight effects.
- Retatrutide MASLD phase 2a (PubMed) ↗· Nature Medicine 2024 liver-fat sub-study; large reductions in hepatic fat.
- ClinicalTrials.gov. TRIUMPH-1 obesity Phase 3 (NCT05929066) ↗· Pivotal Phase 3; topline May 2026 reported up to ~25-30% weight loss at 80 wks.
- ClinicalTrials.gov. Retatrutide T2D Phase 3 (NCT05929079) ↗· Phase 3 in T2D with obesity/overweight; supports A1C + weight claims.
- ClinicalTrials.gov. Retatrutide + cardiovascular disease (NCT05882045) ↗· Phase 3 in obesity + established CV disease; CV-outcome data still pending.
- DailyMed search, retatrutide (no approved label) ↗· Confirms NO FDA-approved finished product exists as of June 2026, the central safety caveat.
- Eli Lilly investor release. TRIUMPH-1 topline ↗· Company topline for pivotal Phase 3; full peer-reviewed publication pending.
The four lenses reflect the evidence and the real-world record as of the last review and will change as data arrives. Real-world signal and reported feedback are anecdote, not proof. Nothing here is medical advice or a prescription.